CSIMarket Company Name, Ticker, Customers, else..
 
In8bio Inc   (INAB)
Other Ticker:  
 
 
Price: $0.3055 $-0.01 -3.476%
Day's High: $0.32 Week Perf: 1.13 %
Day's Low: $ 0.30 30 Day Perf: -49.33 %
Volume (M): 122 52 Wk High: $ 2.48
Volume (M$): $ 37 52 Wk Avg: $1.03
Open: $0.32 52 Wk Low: $0.28



 Market Capitalization (Millions $) 10
 Shares Outstanding (Millions) 32
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -30
 Cash Flow (TTM) (Millions $) -15
 Capital Exp. (TTM) (Millions $) 4

In8bio Inc
In8bio Inc is a biotechnology company that specializes in the development of innovative and targeted cell therapies for the treatment of cancer and other diseases. The company focuses on utilizing its proprietary technologies and expertise to engineer T cells, which are important immune cells, to recognize and kill specific cancer cells. In8bio's approach aims to improve the effectiveness and safety of cell therapies, potentially offering better treatment options for patients. The company is dedicated to advancing the field of cell therapy and bringing novel therapies to market to address unmet medical needs.


   Company Address: 350 5th Avenue New York 10118 NY
   Company Phone Number: 600-6438   Stock Exchange / Ticker: NASDAQ INAB


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Management Announcement

IN8bio's Resolute Focus on INB-100 Ignites Hope for Acute Myeloid Leukemia Patients amid Financial Hurdles,

Published Wed, Sep 4 2024 8:01 PM UTC

IN8bio's Strategic Prioritization: Focusing on INB-100 for Acute Myeloid Leukemia amidst Market Challenges
In a recent announcement, IN8bio Inc unveiled its clinical pipeline prioritization strategy, with an emphasis on INB-100, a potential breakthrough therapy for Acute Myeloid Leukemia (AML). As the company aims to address the pressing need for effective treatments in ...
Clinical Study

IN8bio Pioneering the Frontiers of Gamma-Delta T Cell Therapy in Oncology,

Published Mon, Aug 12 2024 12:05 PM UTC

Clinical Advancements in Gamma-Delta T Cell Therapy: IN8bio's Breakthroughs in OncologyRecent developments in the field of oncology have seen IN8bio, a leader in gamma-delta T cell therapy, make significant strides in the treatment of hematological malignancies and solid tumors. The company has reported promising results from its clinical trials, solidifying its position at...
Clinical Study

IN8bios Groundbreaking Advances in Gamma-Delta T Cell Therapy Show Promise in Cancer Treatment

Published Mon, Jun 3 2024 10:05 AM UTC

In recent groundbreaking presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the American Association for Cancer Research (AACR) 2024, IN8bio, a leading biotechnology company, has showcased significant advancements in their Gamma-Delta T cell therapy platform. The company's findings demonstrate promising potential in the field of cancer ...
Clinical Study

IN8bio's INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma: Unlocking New Hope for Patients

Published Thu, May 23 2024 9:00 PM UTC

The emerging field of precision medicine holds tremendous promise for revolutionizing cancer treatment. In this article, we delve into the latest groundbreaking developments presented by IN8bio at the highly anticipated 2024 ASCO Annual Meeting. The pharmaceutical company shares its eagerly awaited Phase 1 study data on INB-200, shedding light on its potential impact in trea...
Clinical Study

Pioneering Advances in Gamma-Delta T Cell Therapy Manufacturing: A Game-Changer in Cancer Treatment

Published Mon, May 13 2024 12:01 PM UTC

In the realm of cancer therapy, the pursuit of innovative and effective treatments has been relentless. Over the years, immunotherapy has emerged as a promising avenue, with the potential to revolutionize the way we combat cancer. Among the various immunotherapeutic approaches, gamma-delta (??) T cell therapy has garnered significant attention due to its remarkable potential...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com